Abstract. We have studied the relationship between in vivo insulin-mediated glucose disposal rates, muscle glycogen content, and muscle glycogen synthase activity in 25 southwest American Indians with normal glucose tolerance and with varying degrees of glucose intolerance. Insulin-mediated glucose disposal (M) was measured by using the hyperinsulinemic euglycemic clamp technique at plasma insulin concentrations of 134±7 and 1709±72 AU/ml, with simultaneous indirect calorimetry to assess glucose oxidation and storage rates.
Introduction
Recent studies in man have shown that most of an oral or intravenous glucose load is taken up by muscle (1, 2) . Fur [1185] [1186] [1187] [1188] [1189] [1190] thermore, insulin-mediated glucose disposal by muscle appears to be predominantly by nonoxidative pathways, presumably glycogen synthesis (1) , and the rate-controlling enzyme in this process is glycogen synthase (3) . We have previously reported (4) a good correlation between muscle glycogen synthase %I activity (percent active independent ofglucose-6-phosphate [G-6-P])' and insulin-mediated glucose disposal rates in Caucasian males following glycogen-depleting exercise. This suggested that glycogen synthase activity may be an important determinant of in vivo insulin-mediated glucose disposal rates in glycogendepleted man.
To ascertain if muscle glycogen synthase activity may be a determinant ofinsulin-mediated glucose disposal rates in rested, glycogen-replete subjects, we have analyzed the relationship between muscle glycogen synthase activity and in vivo insulin action in a group of southwest American Indians. The relationships were e~xamined over a broad range ofinsulin-mediated glucose disposal rates by studying subjects with normal glucose tolerance and varying degrees of glucose intolerance. The hyperinsulinemic euglycemic clamp technique was used to assess in vivo insulin action at a low and very high plasma insulin concentration. Simultaneous indirect calorimetry was used to estimate insulin-mediated glucose oxidation and storage rates. These measures of insulin action were then compared to the muscle glycogen content and glycogen synthase activity before and after the euglycemic clamp procedure.
Methods
Subjects. 25 southwest American Indians, 14 females and 11 males, were admitted to the clinical research ward for study. Their characteristics are shown in Table I . After written informed consent was obtained, all subjects were physically examined and a 12 lead electrocardiogram recorded. After an overnight fast, blood was drawn for complete blood count, liver function tests, blood-urea nitrogen, creatinine, electrolytes, 1. Abbreviations used in this paper: ffm, fat-free mass; G-6-P, glucose-6-phosphate; GSLo, glycogen synthase activity measured at a low G-6-P (0.17 mM) concentration; %GSLo, glycogen synthase activity measured at a low G-6-P concentration relative to the activity in the presence of high G-6-P; %I activity, percent glycogen synthase activity independent of G-6-P; M, insulin-mediated glucose disposal rate; Ra, appearance rate. Euglycemic clamp (See Fig. 1 ). After the oral glucose tolerance test and at 0500 h after a 10-h overnight fast, an intravenous catheter was 0 1 2 3 4 5 6 7 8 9 10 TIME (hours) [3-H3] (7, 8, 9) . After the start of the initial insulin infusion, a variable infusion of 20% glucose was given as necessary to maintain the plasma glucose concentration at 100 mg/ 100 ml for all subjects. Thus, in the hyperglycemic subjects, the glucose infusion was not begun until the plasma glucose concentration had declined to 100 mg/100 ml. Blood for plasma glucose concentration was drawn every 5 min throughout the test. The mean plasma glucose concentration for all subjects was 102±0.5 mg/100 ml (mean C.V. = 2.0±0.1%) during the last 40 min of the low-dose insulin infusion, and was 101±0.5 mg/100 ml (mean C.V. = 3.0±0.1%) during the last 40 min ofthe high-dose insulin infusion. Blood for plasma [3-H3] glucose specific activity was drawn every 10 min from 300-340 and from 380-420 min to determine the [3-H3]glucose specific activity for calculation of the glucose appearance rate (see below).
Indirect calorimetry. Beginning 1 h before the end of the low-dose insulin infusion ( Fig. 1 (Fig. 1) , a percutaneous biopsy of the vastus lateralis muscle was performed. The specimen was immediately frozen in liquid nitrogen, stored at -70°C, and later, assayed for glycogen content and glycogen synthase activity. The muscle biopsy was repeated at the end of the insulin infusion. The method of Nuttall et al. (11) was modified for homogenization of muscle biopsies. Aliquots of the homogenate were stored at -20°C for the determination of glycogen content. The remaining homogenate was centrifuged at 8,000 g for 10 min and aliquots of the supernatant were stored at -20°C for protein assay or used immediately for determination ofglycogen synthase activity. Previously, we (4) and others (12) have reported glycogen synthase activity as the "%I activity" or the percent of active enzyme in the absence of G-6-P.
To more closely match in vivo conditions, we now have measured glycogen synthase activity at a low G-6-P concentration (0.17 mM) in the presence of 0.14 mM UDP glucose (13). Maximal activity was measured at high G-6-P (7.2 mM) and in the presence of 0.14 mM UDP glucose. Activity was measured by using UDP [ (17) . The total glucose disposal rate (M) is equal to the Ra. When the isotopically determined Ra was equal to the exogenous glucose infusion rate, the endogenous glucose production was assumed to be fully suppressed, and then, M equals the exogenous glucose infusion rate. These data were calculated for each 20-min period between 300-340 and 380-400 min, or during the last 40 min of the low-and high-dose insulin infusions, and then averaged to calculate the mean total glucose disposal rate during this period of both insulin infusions. The insulin-stimulated carbohydrate oxidation rates were calculated from the indirect calorimetric data by also averaging the data for the last 40 min during the low-and high-dose insulin infusion. The carbohydrate storage rate was estimated by subtracting the carbohydrate oxidation rate from the total glucose disposal rate, during both insulin infusions. Plasma insulin concentrations were determined by radioimmunoassay, and tritiated glucose specific activity in blood samples was determined after precipitating protein with perchloric acid as described by others (18).
Statistics. All data are expressed as the mean±SEM. All statistical analyses were calculated using Statistical Analysis System, SAS Institute, Inc., Cary, NC. Simple correlations are Pearson product-moment correlations.
Results
Muscle glycogen content and glycogen synthase activity, measured at a low G-6-P (0.17 mM) concentration (GSLo) before and after the euglycemic clamp, are listed in Table II . Muscle glycogen content ranged from 83 to 258 mg/g protein and increased in 18 subjects following the euglycemic clamp. Muscle GSLo ranged from 1.5 to 3.9 nmol/min -mg protein prior to the insulin infusion and increased in 21 of the 25 subjects following the euglycemic clamp. The change in muscle GSLo in response to the insulin and glucose infusion was significantly correlated with the change in muscle glycogen content (r = 0.46, P < 0.03) (Fig. 2) .
Although the correlation was significant, it was a weaker relationship than might be predicted if glycogen synthesis rates are accurately reflected by glycogen synthase activity. This sug- Relationship between the change in muscle glycogen synthase activity and the change in muscle glycogen content following the euglycemic clamp procedure. Muscle glycogen synthase activity was determined in the presence of 0.17 mM G-6-P and 0.14 mM UDP glucose. r = 0.46, P < 0.03. correlated with the change in muscle GSLo (r = 0.78, P < 0.001). The relationships between %GSLo or GSLo and in vivo insulin action were similar (vide infra). However, %GSLo is a relative term and does not indicate the units of enzyme activity present in the muscle. Therefore, we have reported the data as GSLo (activity in the presence of 0.17 mM G-6-P and 0.14 mM UDP glucose). This is a quantitative assessment, in vitro, ofthe ability of the muscle enzyme to convert glucose to glycogen.
The insulin-mediated glucose disposal (M) and storage rates are expressed as milligrams per kilogram of fat-free mass per minute. As can be seen in Fig. 3 , insulin-mediated glucose storage rates were distributed over a broad range during both the low (-0.1 1-2.42 mg/kg-fat-free mass [fflm] * min) and high (-0.22-9.95 mg/kg-ffm * min) dose insulin infusions as were the M values (1.79-6.10 mg/kg-ffm * min and 3.21 to 15 .91 mg/kg-ffm * min). M values were well correlated with insulin-mediated glucose storage rates during the low (r = 0.82, P < 0.0001) and high (r = 0.97, P < 0.0001) dose insulin infusions, respectively.
There was a significant correlation between the muscle GSLo at the end of the insulin infusions and glucose storage rates measured during the low (r = 0.50, P < 0.02) (Fig. 3 A) and high (r = 0.78, P < 0.0001) dose insulin infusions (Fig. 3 B) . Similarly, the change in GSLo (after insulin infusion minus before insulin infusion) also correlated with the glucose storage rates during the insulin infusions (r = 0.59, P < 0.01 and r = 0.74, P < 0.0001). Muscle GSLo at the end of the euglycemic clamp also correlated with M during the low (r = 0.66, P < 0.001) and high (0.76, P < 0.0001) dose insulin infusion. Similarly, the change in GSLo also correlated with M during the insulin infusions (r = 0.68, P < 0.001 and r = 0.70, P < 0.001). Muscle glycogen content, before or after the euglycemic clamp, and the change in muscle glycogen content following the insulin infusion did not correlate significantly with M or glucose storage rates.
Discussion
Previous studies in man have shown that glucose given orally or intravenously is taken up predominantly by muscle (1, 2) . In addition, DeFronzo et al. (1) reported that insulin-mediated glucose disposal into muscle was primarily by nonoxidative pathways, presumably glycogen synthesis. These data suggested, therefore, that reductions in insulin-mediated glucose disposal rates observed in man might be secondary to abnormalities of glycogen synthesis. In addition, since glycogen synthase is known to be the rate-controlling enzyme for muscle glycogen synthesis (3), we hypothesized that decreased glycogen synthase activity may be related to decreased insulin action in vivo in man. Our results show that there is a good correlation between muscle glycogen synthase activity and in vivo insulin-mediated glucose storage rates as well as net glucose disposal rates in glucosetolerant and diabetic subjects. The correlation coefficients between these parameters were higher at supraphysiologic insulin concentrations probably because the muscle biopsies were done after the high-dose insulin infusion and not directly after the low-dose insulin infusion. Nonetheless, muscle glycogen synthase Muscle glycogen synthase activity ( nmol/min-mg protein) Figure 3 . Relationship between the glucose storage rates and muscle glycogen synthase activity measured at the end of the insulin infusions; at a mean plasma insulin concentration of (A) 134±7 MU/ml (r = 0.50, P < 0.02) and (B) 1709±72 MU/ml (r = 0.78, P < 0.0001). Muscle glycogen synthase activity was determined in the presence of 0.17 mM G-6-P and 0.14 mM UDP glucose. There was a weak, but significant correlation between the change in muscle glycogen content and the change in glycogen synthase activity in response to the insulin infusions in this study (r = 0.46, P < 0.03). This suggests that muscle glycogen synthase activity does indeed reflect the capability ofthe subjects to synthesize glycogen in response to insulin. However, in seven subjects, there was no measured increase in muscle glycogen content. Three of these subjects (Nos. 10, 14, and 19) had little or no increase in glycogen synthase activity during the insulin and glucose infusions, and therefore, would be expected to have very little change in muscle glycogen content. When the small amount of glucose infused in these subjects is distributed over the entire muscle mass ofthe body, the actual change in muscle glycogen concentration would be so small as to be undetectable by current methods. In four of these seven subjects (Nos. 3, 9, 12, and 21), a measurable increase in muscle glycogen content would have been expected from the measured glycogen synthase activation and glucose storage rates. There was no apparent technical explanation for the unusual glycogen results in these subjects so their results were included. Despite these three subjects, there was still a significant correlation between the change in glycogen synthase activity and glycogen content during the euglycemic clamp procedure. Muscle glycogen concentration is a result of both rates of glycogen synthesis and glycogenolysis. It is quite possible that newly synthesized glycogen is metabolized during the euglycemic clamp procedure as observed in rats following oral glucose (20) . The increased phosphorylase a activity in the muscle tissue in four of six subjects in this study provides preliminary evidence in man that glycogenolysis increases in some subjects during the euglycemic clamp procedure. Muscle glycogen synthase activity only estimates glycogen synthesis rates and not rates of glycogenolysis. A higher correlation between glycogen synthase activation and change in muscle glycogen content might occur if glycogenolysis was absent during the insulin infusion. In vivo rates of glycogenolysis will need to be more thoroughly assessed during insulin infusions to properly interpret the relationship between the change in muscle glycogen content and in vivo insulin action. However, this does not detract from the importance of the relationship between glycogen synthase activity and in vivo insulin action. Glycogen synthase activity estimates glycogen synthesis rates, and the good correlation with insulin-mediated glucose disposal rates observed in this study emphasizes the possible importance of glycogen synthesis in muscle in determining in vivo insulin-mediated glucose disposal rates in man. However, establishing a direct cause and effect relationship between muscle glycogen synthase activity and in vivo insulin-mediated glucose disposal rates will require further study.
